IMAGEENS
IMAGEENS, a Paris-based medical Artificial Intelligence (AI) startup developing software solutions for the analysis of medical images, has secured 1.2Mn€ in seed financing. The round was led by Anaxago, with a participation from BADGE (Business Angels des Grandes Ecoles), COALESCENCE, and existing IMAGEENS investors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210415005466/en/
IMAGEENS' software solutions allow radiologists, cardiologists and vascular surgeons to make personalized decisions and to better assess the cardiovascular risk of their patients, thanks to highly accurate medical imaging data.
The funding will allow IMAGEENS to accelerate the development and commercialization of ArtFun+, an artificial intelligence software and its prognostic biomarkers for cardiovascular imaging, and LABEL, an algorithmic solution for the automatic classification and valorization of medical imaging data. It will also allow to strengthen its team with key R&D talents and build its commercial team to scale the deployment of its software solutions.
"We are delighted to have been able to quickly complete this round table in collaboration with ANAXAGO. We will be able to announce the launch of several strategic projects as well as key hires in the coming months, which will be the cornerstones of IMAGEENS' development over the next few years," said Robert Baldwin, CEO of IMAGEENS .
ArtFun+ stems from the US National Institute of Health (NIH)-funded Multi-Ethnic Study of Atherosclerosis (MESA) which studied the prognostic power of imaging biomarkers on a multi-ethnic cohort of 3675 patients across the United States. In the study, the imaging biomarkers of ArtFun+ were shown to be highly predictive of death and hard cardiovascular for patients between 45 and 84 years old. Beyond the MESA trial, the imaging biomarkers of ArtFun+ were studied in 77 scientific publications and used in 31 leading clinical centers around the globe.
Today, IMAGEENS is in the process of obtaining FDA and CE-clearance for ArtFun+ in routine cardiovascular care to complement to cardiac MRI exams with cardiovascular risk biomarkers enabling improved follow-up and surgical decisions in ischemic cardiopathies, acute coronary syndrome, and aortic aneurysms.
Since late 2020, IMAGEENS has also developed a complementary business to its diagnostic solutions, by helping Europe’s largest medical data warehouses improve the quality of their medical data and use it for R&D and AI-training purposes. By working with leading medical institutions such as the AP-HP in Paris, IMAGEENS has developed a comprehensive set of image classification algorithms that automatically create metadata allowing the data warehouses to get a detailed understanding of the databases’ content, and the ability to precisely query the medical data to setup cohorts for R&D and AI-training projects.
ABOUT IMAGEENS
Founded in 2017, IMAGEENS develops software solutions for doctors to leverage the full potential of advanced medical imaging data. IMAGEENS commercializes two products: ArtFun+, an innovative software to calculate vascular stiffness and flow imaging biomarkers that are predictive of patients’ long-term risk of death and hard cardiovascular events, and LABEL, a set of image classification algorithms that enable large medical data warehouses to precisely query and create data cohorts for R&D and AI-training projects.
ABOUT ANAXAGO
Created in 2012, the Anaxago group is the first 100% digital private neo-bank, accessible to the greatest number of people, combining impact and performance. With more than 100,000 members, 250 companies and real estate projects financed since its creation and more than 250 million euros collected, Anaxago stands out for the selectivity and the support of the investment projects proposed on its platform. Anaxago is an independent group, majority owned by its founders, and currently has 40 employees. The investment in IMAGEENS was led by Alex Heraud and Gaston Vasseur. Anaxago counsels: M Guilain Hippolyte, Reed Smith LLP.
www.anaxago.com
ABOUT BADGE
Created in 2004 Les Business Angels des Grandes Ecoles is one of the largest networks of Business Angels in France. The mission is to support the development of emerging innovative projects with high growth potential. Since 2005 BADGE has financed 188 projects with 38 M€, having generated a total financing of more than 100 M€.
www.business-angels.info
ABOUT COALESCENCE
Coalescence is a network of Business Angels sharing the same values; they wish to promote the growth of young innovative projects. Beyond finance the members of Coalescence bring kind support with their various professional background.
www.coalescence.fr
View source version on businesswire.com: https://www.businesswire.com/news/home/20210415005466/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cooler Master Expands Its Thermal Excellence with Hyper 212 3DHP Series and V4 Alpha 3DHP Black20.10.2025 12:01:00 CEST | Press release
Reliable, Quiet Single-Tower Air Coolers Built on Patented 3DHP Cooler Master, a global leader in PC components and tech lifestyle solutions, today announced availability of the Hyper 212 3DHP series and the V4 Alpha 3DHP Black air coolers. Both use Cooler Master’s patented 3DHP Technology the company’s latest cooling innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020694683/en/ The new air coolers from Cooler Master: the Hyper 212 3DHP series and the V4 Alpha 3DHP Black. “With 3DHP, we move past pipe-count and focus on results,” said Matteo Stracciari, GM of Cooler Master EU. “Less heat. More dependable performance. Less noise. More long-term reliability. All in compact single-tower builds.” 3DHP: Less is More 3DHP reengineers the heat pipe itself for better evaporation, condensation, and flow. A third pipe endpoint and a precision T-joint increase heat pickup and flow, turning fewer pipes into more effective
BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 202520.10.2025 12:00:00 CEST | Press release
New data from two pivotal TEVIMBRA studies – RATIONALE-307 and -312 – reinforce the PD-1 inhibitor’s proven clinical benefit in both NSCLC and ES-SCLCEarly data from investigational HPK1 inhibitor BGB-26808, in combination with TEVIMBRA, show promise in advanced solid tumors BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of data from two pivotal Phase 3 trials – RATIONALE-307 and 312 – offering new evidence of the benefits of its PD-1 inhibitor, TEVIMBRA® (tislelizumab), at the European Society of Medical Oncology 2025 Congress (ESMO 2025) in Berlin, Germany, October 17-21. The results reinforce TEVIMBRA’s consistent and durable efficacy across lung cancer subtypes, including non-small cell lung cancer (NSCLC) and extensive-stage small cell lung cancer (ES-SCLC). In addition, the first clinical data from BeOne’s investigational HPK1 inhibitor, BGB-26808, as a single agent and in combination with TEVIMBRA, will b
SunRock Biopharma and Chime Biologics Announce Strategic Collaboration to Advance Development of Anti-CCR9 Antibody SRB520.10.2025 11:00:00 CEST | Press release
SunRock Biopharma, a biotechnology company focused on developing next-generation therapeutic antibodies, and Chime Biologics, a global leading contract development and manufacturing organization (CDMO), today announced a strategic collaboration for the development of SRB5, a novel anti-CCR9 monoclonal antibody targeting inflammatory bowel disease (IBD), with potential expansion into other immune-mediated inflammatory indications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251019831972/en/ The scientific team of SunRock Biopharma. SRB5 is a humanized monoclonal antibody with enhanced ADCC properties, designed to selectively deplete CCR9+ cells involved in chronic intestinal inflammation. It is the latest advancement in SunRock’s anti-CCR9 platform and represents a significant advance in a selective therapeutic approach for treating diseases such as Crohn’s disease and ulcerative colitis. Through this partnership, SunRock
New Needle-Free Treatment Option for Life-Threatening Anaphylaxis, EURneffy®, Now Available in the UK20.10.2025 10:01:00 CEST | Press release
For decades, traditional adrenaline auto-injectors (AAIs) have been the only available treatment for anaphylaxis—a life-threatening allergic reaction.1,2 Yet from today, the UK’s first needle-free emergency anaphylaxis treatment, the EURneffy® nasal adrenaline spray, is available on prescription.3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020480135/en/ EURneffy® 2 mg nasal spray offers a simple-to-use,3,4 pocket-sized alternative to traditional AAIs, with the potential to transform the lives of those with severe allergies in the UK. It is designed to be portable and ready-to-use in emergencies,3 offering a new alternative to traditional AAIs, including for those who struggle with needles or need a more convenient option they can rely on. EURneffy® also has a longer shelf life and can withstand temperature changes better than traditional AAIs,3,5 meaning fewer trips to the GP for a new prescription. Simon Williams, Ch
Leading Global Businesses Unite to Launch Carbon Measures20.10.2025 10:00:00 CEST | Press release
New coalition to advance global carbon accounting framework and champion market-based solutions that drive emissions reductionsAmy Brachio, former Ernst & Young global vice chair and head of sustainability, named CEO Carbon Measures, a new global coalition representing major businesses from diverse industries and geographies, launched today to establish a more accurate carbon accounting framework and drive market-based solutions to reduce emissions at the lowest cost. The coalition’s work will leverage sound science and the principles of financial accounting to help enable a ledger-based carbon accounting framework that is substantially more accurate, eliminates double counting and addresses current information gaps. By better tracking emissions through the global economy, this new framework will help businesses differentiate their products and governments make more informed policy decisions. Carbon Measures is calling for new policy that unlocks innovation, competition and the power o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom